Literature DB >> 26344409

A Flow Cytometric Clonogenic Assay Reveals the Single-Cell Potency of Doxorubicin.

Katie F Maass1, Chethana Kulkarni2, Mohiuddin A Quadir3, Paula T Hammond1, Alison M Betts4, Karl Dane Wittrup5.   

Abstract

Standard cell proliferation assays use bulk media drug concentration to ascertain the potency of chemotherapeutic drugs; however, the relevant quantity is clearly the amount of drug actually taken up by the cell. To address this discrepancy, we have developed a flow cytometric clonogenic assay to correlate the amount of drug in a single cell with the cell's ability to proliferate using a cell tracing dye and doxorubicin, a naturally fluorescent chemotherapeutic drug. By varying doxorubicin concentration in the media, length of treatment time, and treatment with verapamil, an efflux pump inhibitor, we introduced 10(5) -10(10) doxorubicin molecules per cell; then used a dye-dilution assay to simultaneously assess the number of cell divisions. We find that a cell's ability to proliferate is a surprisingly conserved function of the number of intracellular doxorubicin molecules, resulting in single-cell IC50 values of 4-12 million intracellular doxorubicin molecules. The developed assay is a straightforward method for understanding a drug's single-cell potency and can be used for any fluorescent or fluorescently labeled drug, including nanoparticles or antibody-drug conjugates.
© 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  cancer chemotherapy; cell lines; drug effects; efflux pumps; pharmacodynamics

Mesh:

Substances:

Year:  2015        PMID: 26344409      PMCID: PMC4706798          DOI: 10.1002/jps.24631

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  42 in total

Review 1.  Compilation of 222 drugs' plasma protein binding data and guidance for study designs.

Authors:  Fengling Zhang; Jinpin Xue; Jingwei Shao; Li Jia
Journal:  Drug Discov Today       Date:  2011-12-23       Impact factor: 7.851

Review 2.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

Review 3.  Cellular chemosensitivity assays: an overview.

Authors:  Venil N Sumantran
Journal:  Methods Mol Biol       Date:  2011

4.  Rapid measurement of intracellular unbound drug concentrations.

Authors:  André Mateus; Pär Matsson; Per Artursson
Journal:  Mol Pharm       Date:  2013-05-15       Impact factor: 4.939

5.  Analysis of doxorubicin uptake in single human leukemia K562 cells using capillary electrophoresis coupled with laser-induced fluorescence detection.

Authors:  Bin Deng; Zhiming Wang; Jian Song; Yuxiu Xiao; Dan Chen; Jun Huang
Journal:  Anal Bioanal Chem       Date:  2011-08-20       Impact factor: 4.142

Review 6.  Antibody-drug conjugates - a perfect synergy.

Authors:  John R Adair; Philip W Howard; John A Hartley; David G Williams; Kerry A Chester
Journal:  Expert Opin Biol Ther       Date:  2012-06-01       Impact factor: 4.388

7.  Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation.

Authors:  Ondřej Hovorka; Vladimír Subr; David Větvička; Lubomír Kovář; Jiří Strohalm; Martin Strohalm; Aleš Benda; Martin Hof; Karel Ulbrich; Blanka Ríhová
Journal:  Eur J Pharm Biopharm       Date:  2010-07-16       Impact factor: 5.571

8.  Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.

Authors:  Greg M Thurber; Katy S Yang; Thomas Reiner; Rainer H Kohler; Peter Sorger; Tim Mitchison; Ralph Weissleder
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 9.  Choosing the right cell line for breast cancer research.

Authors:  Deborah L Holliday; Valerie Speirs
Journal:  Breast Cancer Res       Date:  2011-08-12       Impact factor: 6.466

10.  DrugBank 4.0: shedding new light on drug metabolism.

Authors:  Vivian Law; Craig Knox; Yannick Djoumbou; Tim Jewison; An Chi Guo; Yifeng Liu; Adam Maciejewski; David Arndt; Michael Wilson; Vanessa Neveu; Alexandra Tang; Geraldine Gabriel; Carol Ly; Sakina Adamjee; Zerihun T Dame; Beomsoo Han; You Zhou; David S Wishart
Journal:  Nucleic Acids Res       Date:  2013-11-06       Impact factor: 16.971

View more
  3 in total

1.  Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design.

Authors:  Katie F Maass; Chethana Kulkarni; Alison M Betts; K Dane Wittrup
Journal:  AAPS J       Date:  2016-02-24       Impact factor: 4.009

2.  Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.

Authors:  Aman P Singh; Leiming Guo; Ashwni Verma; Gloria Gao-Li Wong; Greg M Thurber; Dhaval K Shah
Journal:  AAPS J       Date:  2020-01-14       Impact factor: 4.009

3.  A "Dual" Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC.

Authors:  Aman P Singh; Dhaval K Shah
Journal:  J Pharm Sci       Date:  2019-02-18       Impact factor: 3.534

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.